SLC35D1 Inhibitors
Chemical inhibitors of SLC35D1 can serve to hinder its function through various mechanisms that interrupt the protein transport and glycosylation processes within the cellular environment. Brefeldin A, for instance, disrupts the protein transport from the endoplasmic reticulum to the Golgi apparatus, a step crucial for the operation of SLC35D1, which is intimately involved in shuttling nucleotide sugars into the Golgi. This inhibition of transport can directly impede the glycosylation functions that SLC35D1 supports. Similarly, Monensin acts as an ionophore that alters intracellular pH and sodium levels, thus disturbing the ion gradients that are essential for the nucleotide sugar transport activity of SLC35D1. Swainsonine and Tunicamycin target glycosylation indirectly; while Swainsonine inhibits mannosidase II leading to misprocessed glycoproteins, Tunicamycin prevents the initial steps of N-linked glycosylation, both potentially causing a Golgi stress response that could inhibit the activity of SLC35D1 through feedback mechanisms or overload.
Continuing with this theme, Castanospermine and Deoxynojirimycin inhibit glucosidases, enzymes responsible for trimming glycoproteins, which can lead to a backlog of glycoprotein processing, indirectly impeding SLC35D1 by affecting the availability of its substrates. Kifunensine's inhibition of mannosidase I in the ER could provoke a similar effect, as it could result in misfolded glycoproteins that stress the ER, possibly causing an indirect inhibition of SLC35D1 by altering glycosylation processing. The inhibitors Miglustat, Fumonisin B1, and N-butyldeoxynojirimycin disrupt various aspects of sphingolipid and glycolipid synthesis, which are critical for membrane composition and could thus inhibit SLC35D1 by modifying the lipid environment necessary for its function. Bafilomycin A1, which targets V-ATPase and disrupts organelle acidification, would affect the pH gradient in the Golgi, potentially inhibiting SLC35D1 as the protein's activity is contingent on this gradient.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A inhibits protein transport from the endoplasmic reticulum to the Golgi apparatus, thereby inhibiting the function of SLC35D1, which is involved in the transport of nucleotide sugars into the Golgi for glycosylation processes. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin acts as an ionophore that disrupts Golgi function by altering intracellular pH and sodium concentrations. This can inhibit SLC35D1 by affecting the ion gradients necessary for its nucleotide sugar transport activity. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $135.00 $246.00 $619.00 $799.00 $1796.00 | 6 | |
Swainsonine inhibits mannosidase II, which could lead to the accumulation of misprocessed glycoproteins in the Golgi, a situation that potentially inhibits SLC35D1 by overload or feedback inhibition mechanisms. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation by blocking the transfer of N-acetylglucosamine to dolichol phosphate, which could lead to Golgi stress and potential inhibition of SLC35D1 activity due to disruption of normal glycosylation traffic. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $180.00 $620.00 | 10 | |
Castanospermine inhibits glucosidases involved in the trimming of glycoproteins within the ER and Golgi, potentially leading to glycoprotein processing defects that could inhibit SLC35D1 by disrupting its substrate availability. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $72.00 $142.00 | ||
Deoxynojirimycin inhibits glucosidase enzymes, potentially causing a build-up of improperly folded glycoproteins in the ER, which can indirectly inhibit SLC35D1 by perturbing ER-Golgi trafficking. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $132.00 $529.00 $1005.00 $6125.00 | 25 | |
Kifunensine inhibits mannosidase I in the ER, which could lead to misfolded glycoproteins and ER stress, potentially inhibiting SLC35D1 by affecting the proper glycosylation processing needed for its function. | ||||||
Fumonisin B1 | 116355-83-0 | sc-201395 sc-201395A | 1 mg 5 mg | $117.00 $469.00 | 18 | |
Fumonisin B1 inhibits ceramide synthase, leading to changes in sphingolipid metabolism that could inhibit SLC35D1 by disturbing the membrane lipid composition and associated transport functions. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Bafilomycin A1 is a V-ATPase inhibitor that disrupts organelle acidification, including in the Golgi, where SLC35D1 operates, potentially inhibiting the protein by affecting the pH gradient required for its activity. | ||||||
N-Butyldeoxynojirimycin·HCl | 210110-90-0 | sc-201398 sc-201398A sc-201398B | 5 mg 25 mg 50 mg | $148.00 $492.00 $928.00 | 4 | |
N-butyldeoxynojirimycin inhibits glucosylceramide synthase, potentially leading to glycolipid profile alterations and inhibiting SLC35D1 by changing the membrane dynamics where it operates. | ||||||